| Literature DB >> 31530094 |
Chunyan Liu1, Xiuli Wang1,2, Youzhong Zhang2.
Abstract
Cancer cells undergo metabolic changes that support their malignant growth. These changes are often associated with increased expression of the rate-limiting glycolytic enzyme hexokinase 2. Hexokinase 2 is an enzyme that catalyzes the conversion of glucose to glucose-6-phosphate. In this study, we utilized Gene Expression Profiling Interactive Analysis (GEPIA) database analysis and clinical sample analysis to find that hexokinase 2 was highly expressed in cervical cancer. Furthermore, we found that high hexokinase 2 expression in cervical cancer demonstrated a positive correlation with tumor size (P = .009696), pathological grade (P = .028551), and prognosis (P = .00069) but not with age (P = .956201) or lymph node metastasis (P = .131379). At the cellular level, we knocked down the expression of hexokinase 2 in the human cervical cancer cell line SiHa. The results demonstrated that knockdown of hexokinase 2 inhibited the proliferation and migration of SiHa cells and promoted cell apoptosis. During this process, knockdown of hexokinase 2 inhibited phosphorylation of AKT and mammalian target of rapamycin and promoted p53 expression. At the same time, overexpression of human papillomavirus 18 oncogenes E6 and E7 significantly promoted the expression of hexokinase 2. Most importantly, we discovered a novel upstream regulatory microRNA for hexokinase 2: miR-9-5p. Luciferase reporter assays and Western blot assays demonstrated that hexokinase 2 expression was inhibited by miR-9-5p by directly binding its 3'-untranslated region in SiHa cells. Next, we determined that miR-9-5p could suppress the proliferation and migration of SiHa cells and induce apoptosis. In conclusion, we found that hexokinase 2 serves a carcinogenic role in cervical cancer through the miR-9-5p/hexokinase 2/AKT pathway, which serves as the basis for potential therapeutic targets and prognostic indicators.Entities:
Keywords: AKT pathway; HK2; cervical cancer; miR-9-5p; prognosis
Mesh:
Substances:
Year: 2019 PMID: 31530094 PMCID: PMC6751531 DOI: 10.1177/1533033819871306
Source DB: PubMed Journal: Technol Cancer Res Treat ISSN: 1533-0338
HK2 Expression Associated With the Clinicopathological Parameters in Cervical Tumors.
| Clinicopathological Parameters | n | HK2 High, n (%) | HK2 Low, n (%) |
|
|---|---|---|---|---|
| Age, years | ||||
| <50 | 14 | 12 (85.7) | 2 (14.3) | .956201 |
| ≥50 | 22 | 19 (86.4) | 3 (13.6) | |
| Tumor diameter, cm | ||||
| <3 | 11 | 7 (63.6) | 4 (36.4) | .009696a |
| ≥3 | 25 | 24 (96.0) | 1 (4.0) | |
| Lymph node metastasis | ||||
| Yes | 6 | 4 (66.7) | 2 (33.3) | .131379 |
| No | 30 | 27 (90.0) | 3 (10.0) | |
| Pathological grading | ||||
| I-II | 8 | 5 (62.5) | 3 (37.5) | .028551a |
| III-IV | 28 | 26 (92.9) | 2 (7.1) |
Abbreviation: HK2, hexokinase 2.
aP<0.05
Figure 1.Hexokinase 2 (HK2) shows abnormal high expression level in cervical cancer and is significantly associated with prognosis. (A) The boxplot of HK2 expression level. Red and gray boxes represent cervical cancer tissue and normal cervical tissue, respectively. The data came from the Gene Expression Profiling Interactive Analysis (GEPIA) database, including 306 cervical cancer tissues and 13 normal cervical tissues. (B) The prognostic value of HK2 in patients with cervical cancer. Red and blue represent high and low expression of HK2, respectively. The data came from the Cancer Genome Atlas (TCGA) database, including 292 cervical cancer tissue. (C) Immunohistochemical staining of HK2 in cervical cancer tissues and normal cervical tissue. (D) Fluorescence quantitative polymerase chain reaction (PCR) demonstrated the expression of HK2 was reduced by small-interfering RNA1 (siRNA1). (E and F) The protein levels of HK2 were detected by Western blot. (G) The proliferation was detected by CCK8 assay. *P < .05, compared to negative control (NC). All experiments were performed independently 3 times.
HK2 Expression in Cervical Tumors and Normal Cervical Epithelial Tissues.
| Group | n | HK2 expression |
| |
|---|---|---|---|---|
| Low, n (%) | High, n (%) | |||
| Cervical tumors | 36 | 5 (13.9) | 31 (86.1) | <.001a |
| Normal cervical epithelia tissues | 36 | 32 (88.9) | 4 (11.1) | |
Abbreviation: HK2, hexokinase 2.
aP<0.05
Figure 2.Knockdown of hexokinase 2 (HK2) inhibits the migration of SiHa cells and induces apoptosis. (A and B) Transwell assay and (C and D) wound healing assay showed that knockdown of HK2 inhibited cell migration activity. (E and F) Apoptosis was detected by flow cytometry. (G and H) The protein expression was detected by Western blot. (I-J) The messenger RNA (mRNA) expression of E6, E7, and HK2 was detected by Fluorescence quantitative polymerase chain reaction (PCR). *P < .05, compared to negative control (NC). All experiments were performed independently 3 times.
Figure 3.Hexokinase 2 (HK2) is a target protein of miR-9-5p. (A) The sequences of miR-9-5p, HK2 3’-UTR wild-type (WT) and mutant 3’-UTR (Mut). (B) Luciferase reporter assays in SiHa cells transfected with WT or Mut HK2 reporters plus miR-9-5p mimic or miR-NC. (C/D) The protein levels of HK2 were detected by Western blot. (E) The proliferation was detected by CCK8 assay. (F and G) Cell migration was detected by Transwell assay. (H and I) Apoptosis was detected by flow cytometry. *P < .05, compared with MiR-9-5p negative control (miR-NC). All experiments were performed independently three times.